Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by jicoopon Mar 03, 2019 9:51pm
121 Views
Post# 29436311

RE:RE:RE:RE:RE:RE:RE:RE:RE:Any Opinions...

RE:RE:RE:RE:RE:RE:RE:RE:RE:Any Opinions...
Macer wrote:
Hempdoc wrote: Correct me if I’m wrong, but I thought the preclinical studies showed Rutherrin to be effective only to a certain depth of the smooth muscle layer (3 mm) & not the deepest muscle layers.  This suggests an alternative form of treatment may be needed, including intravenous delivery & increasing light wavelength &/or beam width to maximize both deeper absorption of Rutherrin & its activation by PDT.

In the orthotopic rat studies they induced tumors in the bladder muscle wall (I.e. invasive)
they treated the bladder by intravesicular instillation and the used light to activate it.
the were able to demonstrate full thickness tumor necrosis in the bladder muscle. The tumors were 2-3 mm in depth. 
My point is that 1433 demonstrated destruction of muscle invasive bladder cancer. Depth is not important in a limited preclinical study. The bladder is not a super thick muscle to begin with.
macer


Just catching up on the weekend posts and see both bj johnie and bencro have posted, so I think I'm getting back into the single malt scotch liquor cabinet now.
Anyhow, no political opinions for me, just going to clarify one thing from google :

The normal bladder wall had a mean thickness of 2.76 mm when the bladder is almost empty and 1.55 mm when it is distended. There is a linear relationship between bladder fullness and bladder wall thickness; the upper limits are 3 and 5 mm for a full or empty bladder respectively.

Coop
Bullboard Posts